The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses

Conclusion: We recommend anti-EGFR mAbs enhance—but should not replace—current treatment paradigms for locoregionally advanced NPC. Further evidence from phase III clinical trials is required.

Source: Journal of Cancer - December 14, 2018 Category: Cancer & Oncology Authors: Liang Peng, Ze-Long Liu, Cheng Xu, Ling-Long Tang, Xu Liu, Ai-Hua Lin, Ying Sun, Yu-Pei Chen, Jun Ma Tags: Research Paper Source Type: research